Urinary tract infection (UTI) arises in the kidneys, ureter, urethra and bladder because of microbial pathogens in these parts. Urinary tract infections will be uncomplicated or complicated depends on the severity of infection. The penicillin antibiotic that is amoxicillin is used to treat urinary tract infections and it is mainly used as prescribed antibiotic for uncomplicated urinary tract infection. UTI is common bacterial infections affecting many of peoples globally. Continuing urinary tract infection is a main health problem in females worldwide. Patients with spinal cord injury or urinary catheter are mainly contract complicated urinary tract infections.
How Big is the Global Urinary Tract Infection Treatment Market?
The global urinary tract infection treatment market is expected to exceed more than US$ 12.50 Billion by 2028; Growing at a CAGR of more than 2% in the given forecast period.
The urinary tract infection treatment market is segmented on the lines of its drug type, indication, distribution channel and regional. Based on drug type segmentation it covers sulphonamides, azoles and amphotericin B, tetracycline, nitrofurans, aminoglycoside antibiotics, cephalosporin, quinolones and penicillin & combinations. Aminoglycoside antibiotics is further segmented into amikacin and gentamicin. Cephalosporin segmentation covers ceftriaxone, cefuroxime, cefixime and cephalexin. Under quinolones segmentation it covers ciprofloxacin, levofloxacin, nalidixic acid, norfloxacin and others. Penicillin and combinations covers amoxicillin, amoxicillin & clavulanate potassium and others.
The urinary tract infection treatment market is segmented on the lines of its indication like into complicated UTI, recurring complicated UTI, uncomplicated UTI and neurogenic bladder infections. Under distribution channel segmentation it covers hospital pharmacies, gynaecology and urology clinics, drug store, retail pharmacies and online drug stores. The urinary tract infection treatment market’s geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for urinary tract infection treatment and related technologies.
2) Analysis of global market trends, with data from 2020, estimates for 2021 and 2022, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for urinary tract infection treatment.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets for Urinary Tract Infection Treatment Market for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Johnson and Johnsons Private Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer Inc., F.Hoffmann-La Roche Ltd., Novartis AG. and AstraZeneca plc. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Urinary Tract Infection Treatment Market has been segmented as below:
By Drug Type Analysis
• Sulphonamides
• Azoles and Amphotericin B
• Tetracycline
• Nitrofurans
• Aminoglycoside antibiotics
o Amikacin
o Gentamicin
• Cephalosporin
Ceftriaxone
Cefuroxime
Cefixime
Cephalexin
• Quinolones
Ciprofloxacin
Levofloxacin
Nalidixic acid
Norfloxacin
Others
• Penicillin & Combinations
Amoxicillin
Amoxicillin & Clavulanate Potassium
Others
By Indication Analysis
• Complicated UTI
• Recurring Complicated UTI
• Uncomplicated UTI
• Neurogenic Bladder Infections
By Distribution channel Analysis
• Hospital Pharmacies
• Gynaecology and Urology Clinics
• Drug Store
• Retail Pharmacies
• Online Drug Stores
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buy this Report:
1) Obtain the most up to date information available on all urinary tract infection treatment .
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of urinary tract infection treatment data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
1.Introduction
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
2.Research Methodology
2.1 Market Size
1.2 Market Share
1.3 Key Data Points From Secondary Sources
1.4 Key Data Points From Primary Sources
3.Executive Summary
4.Urinary Tract Infection Treatment Market Overview
4.1. Introduction
4.1.1.Urinary Tract Infection Treatment Market Taxonomy
4.1.2.Urinary Tract Infection Treatment Market Definition
4.1.3.Urinary Tract Infection Treatment Market Drug Type Overview
4.1.4.Global Antibiotic Drugs Availability and Resistant Timeline
4.1.5.Clinical Trials
4.2. Urinary Tract Infection Treatment Market Dynamics
4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunity
4.2.4.Trends
4.3. Survey Analysis
4.4. Epidemiology Overview
4.5. PEST Analysis
5.Global Urinary Tract Infection Treatment Market Analysis, By Drug Type
5.1. Introduction
5.1.1.Y-o-Y Growth Comparison, By Drug Type
5.1.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
5.1.3.Market Attractiveness Analysis, By Drug Type
5.2. Market Forecast, By Drug Type
5.2.1.Penicillin & Combinations
5.2.1.1. Absolute $ Opportunity
5.2.1.2. Market Value Forecast
5.2.1.3. Amoxicillin
5.2.1.4. Amoxicillin+ Clavulanate Potassium
5.2.1.5. Others
5.2.2.Quinolones
5.2.2.1. Absolute $ Opportunity
5.2.2.2. Market Value Forecast
5.2.2.3. Ciprofloxacin
5.2.2.4. Levofloxacin
5.2.2.5. Nalidixic acid
5.2.2.6. Norfloxacin
5.2.2.7. Others
5.2.3.Cephalosporin
5.2.3.1. Absolute $ Opportunity
5.2.3.2. Market Value Forecast
5.2.3.3. Cefuroxime
5.2.3.4. Ceftriaxone
5.2.3.5. Cefixime
5.2.3.6. Cephalexin
5.2.4.Aminoglycoside Antibiotics
5.2.4.1. Absolute $ Opportunity
5.2.4.2. Market Value Forecast
5.2.4.3. Amikacin
5.2.4.4. Gentamicin
5.2.5.Sulphonamides
5.2.5.1. Absolute $ Opportunity
5.2.5.2. Market Value Forecast
5.2.5.3. Sulfamethoxazole + Trimethoprim
5.2.6.Azoles and Amphotericin B
5.2.6.1. Absolute $ Opportunity
5.2.6.2. Market Value Forecast
5.2.7.Tetracycline
5.2.7.1. Absolute $ Opportunity
5.2.7.2. Market Value Forecast
5.2.7.3. Doxycycline
5.2.8.Nitrofurans
5.2.8.1. Absolute $ Opportunity
5.2.8.2. Market Value Forecast
5.2.8.3. Nitrofurantoin
5.2.9.Others
5.2.9.1. Absolute $ Opportunity
5.2.9.2. Market Value Forecast
6.Global Urinary Tract Infection Treatment Market Analysis, By Distribution Channel
6.1. Introduction
6.1.1.Y-o-Y Growth Comparison, By Distribution Channel
6.1.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
6.1.3.Market Attractiveness Analysis, By Distribution Channel
6.2. Market Forecast, By Distribution Channel
6.2.1.Hospital Pharmacies
6.2.1.1. Absolute $ Opportunity
6.2.1.2. Market Value Forecast
6.2.2.Gynecology and Urology Clinics
6.2.2.1. Absolute $ Opportunity
6.2.2.2. Market Value Forecast
6.2.3.Drug Store
6.2.3.1. Absolute $ Opportunity
6.2.3.2. Market Value Forecast
6.2.4.Retail Pharmacies
6.2.4.1. Absolute $ Opportunity
6.2.4.2. Market Value Forecast
6.2.5.Online Drug Stores
6.2.5.1. Absolute $ Opportunity
6.2.5.2. Market Value Forecast
7.Global Urinary Tract Infection Treatment Market Analysis, By Indication
7.1. Introduction
7.1.1.Y-o-Y Growth Comparison, By Distribution Channel
7.1.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
7.1.3.Market Attractiveness Analysis, By Distribution Channel
7.2. Market Forecast, By Distribution Channel
7.2.1.Complicated UTI
7.2.1.1. Absolute $ Opportunity
7.2.1.2. Market Value Forecast
7.2.2.Recurring Complicated UTI
7.2.2.1. Absolute $ Opportunity
7.2.2.2. Market Value Forecast
7.2.3.Uncomplicated UTI
7.2.3.1. Absolute $ Opportunity
7.2.3.2. Market Value Forecast
7.2.4.Neurogenic Bladder Infections
7.2.4.1. Absolute $ Opportunity
7.2.4.2. Market Value Forecast
7.2.4.3.
8.Global Urinary Tract Infection Treatment Market Analysis, By Region
8.1. Introduction
8.1.1.Y-o-Y Growth Projections, By Region
8.1.2.Market Share & Basis Point (BPS) Analysis, By Region
8.1.3.Regional Attractiveness Analysis
8.2. Market Forecast, By Region
8.2.1.North America Market Value Forecast
8.2.2.Latin America Market Value Forecast
8.2.3.Europe Market Value Forecast
8.2.4.Eastern Europe Market Value Forecast
8.2.5.APEJ Market Value Forecast
8.2.6.Japan Market Value Forecast
8.2.7.MEA Market Value Forecast
9.North America Urinary Tract Infection Treatment Market Analysis
9.1. Market Value Forecast, By Country
9.1.1.Y-o-Y Growth Projections, By Country
9.1.2.Market Share & Basis Point (BPS) Analysis, By Country
9.1.3.Market Attractiveness Analysis, By Country
9.1.4.US
9.1.5.Canada
9.2. Market Value Forecast, By Drug Type
9.2.1.Y-o-Y Growth Projections, By Drug Type
9.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
9.2.3.Market Attractiveness Analysis, By Drug Type
9.2.4.Penicillin & Combinations
9.2.4.1. Amoxicillin
9.2.4.2. Amoxicillin+ Clavulanate Potassium
9.2.4.3. Others
9.2.5.Quinolones
9.2.5.1. Ciprofloxacin
9.2.5.2. Levofloxacin
9.2.5.3. Nalidixic acid
9.2.5.4. Norfloxacin
9.2.5.5. Others
9.2.6.Cephalosporin
9.2.6.1. Cefuroxime
9.2.6.2. Ceftriaxone
9.2.6.3. Cefixime
9.2.6.4. Cephalexin
9.2.7.Aminoglycoside Antibiotics
9.2.7.1. Amikacin
9.2.7.2. Gentamicin
9.2.8.Sulphonamides
9.2.8.1. Sulfamethoxazole + Trimethoprim
9.2.9.Azoles and Amphotericin B
9.2.10.Tetracycline
9.2.10.1. Doxycycline
9.2.11.Nitrofurans
9.2.11.1. Nitrofurantoin
9.2.12.Others
9.3. Market Value Forecast, By Distribution Channel
9.3.1.Y-o-Y Growth Projections, By Distribution Channel
9.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
9.3.3.Market Attractiveness Analysis, By Distribution Channel
9.3.4.Hospital Pharmacies
9.3.5.Gynecology and Urology Clinics
9.3.6.Drug Stores
9.3.7.Retail Pharmacies
9.3.8.Online Drug Stores
9.4. Market Value Forecast, By Indication
9.4.1.Y-o-Y Growth Projections, By Indication
9.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
9.4.3.Market Attractiveness Analysis, By Indication
9.4.4.Complicated UTI
9.4.5.Recurring Complicated UTI
9.4.6.Uncomplicated UTI
9.4.7.Neurogenic Bladder Infections
10. Latin America Urinary Tract Infection Treatment Market Analysis
10.1. Market Value Forecast, By Country
10.1.1.Y-o-Y Growth Projections, By Country
10.1.2.Market Share & Basis Point (BPS) Analysis, By Country
10.1.3.Market Attractiveness Analysis, By Country
10.1.4.Brazil
10.1.5.Mexico
10.1.6.Rest of Latin America
10.2. Market Value Forecast, By Drug Type
10.2.1.Y-o-Y Growth Projections, By Drug Type
10.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
10.2.3.Market Attractiveness Analysis, By Drug Type
10.2.4.Penicillin & Combinations
10.2.4.1. Amoxicillin
10.2.4.2. Amoxicillin+ Clavulanate Potassium
10.2.4.3. Others
10.2.5.Quinolones
10.2.5.1. Ciprofloxacin
10.2.5.2. Levofloxacin
10.2.5.3. Nalidixic acid
10.2.5.4. Norfloxacin
10.2.5.5. Others
10.2.6.Cephalosporin
10.2.6.1. Cefuroxime
10.2.6.2. Ceftriaxone
10.2.6.3. Cefixime
10.2.6.4. Cephalexin
10.2.7.Aminoglycoside Antibiotics
10.2.7.1. Amikacin
10.2.7.2. Gentamicin
10.2.8.Sulphonamides
10.2.8.1. Sulfamethoxazole + Trimethoprim
10.2.9.Azoles and Amphotericin B
10.2.10. Tetracycline
10.2.10.1.Doxycycline
10.2.11. Nitrofurans
10.2.11.1.Nitrofurantoin
10.2.12. Others
10.3. Market Value Forecast, By Distribution Channel
10.3.1.Y-o-Y Growth Projections, By Distribution Channel
10.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
10.3.3.Market Attractiveness Analysis, By Distribution Channel
10.3.4.Hospital Pharmacies
10.3.5.Gynecology and Urology Clinics
10.3.6.Drug Stores
10.3.7.Retail Pharmacies
10.3.8.Online Drug Stores
10.4. Market Value Forecast, By Indication
10.4.1.Y-o-Y Growth Projections, By Indication
10.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
10.4.3.Market Attractiveness Analysis, By Indication
10.4.4.Complicated UTI
10.4.5.Recurring Complicated UTI
10.4.6.Uncomplicated UTI
10.4.7.Neurogenic Bladder Infections
11. Western Europe Urinary Tract Infection Treatment Market Analysis
11.1. Market Value Forecast, By Country
11.1.1.Y-o-Y Growth Projections, By Country
11.1.2.Market Share & Basis Point (BPS) Analysis, By Country
11.1.3.Market Attractiveness Analysis, By Country
11.1.4.UK
11.1.5.Germany
11.1.6.France
11.1.7.Spain
11.1.8.Italy
11.1.9.Nordic
11.1.10. Benelux
11.1.11. Rest of Western Europe
11.2. Market Value Forecast, By Drug Type
11.2.1.Y-o-Y Growth Projections, By Drug Type
11.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
11.2.3.Market Attractiveness Analysis, By Drug Type
11.2.4.Penicillin & Combinations
11.2.4.1. Amoxicillin
11.2.4.2. Amoxicillin+ Clavulanate Potassium
11.2.4.3. Others
11.2.5.Quinolones
11.2.5.1. Ciprofloxacin
11.2.5.2. Levofloxacin
11.2.5.3. Nalidixic acid
11.2.5.4. Norfloxacin
11.2.5.5. Others
11.2.6.Cephalosporin
11.2.6.1. Cefuroxime
11.2.6.2. Ceftriaxone
11.2.6.3. Cefixime
11.2.6.4. Cephalexin
11.2.7.Aminoglycoside Antibiotics
11.2.7.1. Amikacin
11.2.7.2. Gentamicin
11.2.8.Sulphonamides
11.2.8.1. Sulfamethoxazole + Trimethoprim
11.2.9.Azoles and Amphotericin B
11.2.10. Tetracycline
11.2.10.1.Doxycycline
11.2.11. Nitrofurans
11.2.11.1.Nitrofurantoin
11.2.12. Others
11.3. Market Value Forecast, By Distribution Channel
11.3.1.Y-o-Y Growth Projections, By Distribution Channel
11.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
11.3.3.Market Attractiveness Analysis, By Distribution Channel
11.3.4.Hospital Pharmacies
11.3.5.Gynecology and Urology Clinics
11.3.6.Drug Stores
11.3.7.Retail Pharmacies
11.3.8.Online Drug Stores
11.4. Market Value Forecast, By Indication
11.4.1.Y-o-Y Growth Projections, By Indication
11.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
11.4.3.Market Attractiveness Analysis, By Indication
11.4.4.Complicated UTI
11.4.5.Recurring Complicated UTI
11.4.6.Uncomplicated UTI
11.4.7.Neurogenic Bladder Infections
12. Eastern Europe Urinary Tract Infection Treatment Market Analysis
12.1. Market Value Forecast, By Country
12.1.1.Y-o-Y Growth Projections, By Country
12.1.2.Market Share & Basis Point (BPS) Analysis, By Country
12.1.3.Market Attractiveness Analysis, By Country
12.1.4.Russia
12.1.5.Poland
12.1.6.Rest of Eastern Europe
12.2. Market Value Forecast, By Drug Type
12.2.1.Y-o-Y Growth Projections, By Drug Type
12.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
12.2.3.Market Attractiveness Analysis, By Drug Type
12.2.4.Penicillin & Combinations
12.2.4.1. Amoxicillin
12.2.4.2. Amoxicillin+ Clavulanate Potassium
12.2.4.3. Others
12.2.5.Quinolones
12.2.5.1. Ciprofloxacin
12.2.5.2. Levofloxacin
12.2.5.3. Nalidixic acid
12.2.5.4. Norfloxacin
12.2.5.5. Others
12.2.6.Cephalosporin
12.2.6.1. Cefuroxime
12.2.6.2. Ceftriaxone
12.2.6.3. Cefixime
12.2.6.4. Cephalexin
12.2.7.Aminoglycoside Antibiotics
12.2.7.1. Amikacin
12.2.7.2. Gentamicin
12.2.8.Sulphonamides
12.2.8.1. Sulfamethoxazole + Trimethoprim
12.2.9.Azoles and Amphotericin B
12.2.10. Tetracycline
12.2.10.1.Doxycycline
12.2.11. Nitrofurans
12.2.11.1.Nitrofurantoin
12.2.12. Others
12.3. Market Value Forecast, By Distribution Channel
12.3.1.Y-o-Y Growth Projections, By Distribution Channel
12.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
12.3.3.Market Attractiveness Analysis, By Distribution Channel
12.3.4.Hospital Pharmacies
12.3.5.Gynecology and Urology Clinics
12.3.6.Drug Stores
12.3.7.Retail Pharmacies
12.3.8.Online Drug Stores
12.4. Market Value Forecast, By Indication
12.4.1.Y-o-Y Growth Projections, By Indication
12.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
12.4.3.Market Attractiveness Analysis, By Indication
12.4.4.Complicated UTI
12.4.5.Recurring Complicated UTI
12.4.6.Uncomplicated UTI
12.4.7.Neurogenic Bladder Infections
13. APEJ Urinary Tract Infection Treatment Market Analysis
13.1. Market Value Forecast, By Country
13.1.1.Y-o-Y Growth Projections, By Country
13.1.2.Market Share & Basis Point (BPS) Analysis, By Country
13.1.3.Market Attractiveness Analysis, By Country
13.1.4.China
13.1.5.India
13.1.6.ASEAN
13.1.7.Australia & New Zealand
13.1.8.Rest of APEJ
13.2. Market Value Forecast, By Drug Type
13.2.1.Y-o-Y Growth Projections, By Drug Type
13.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
13.2.3.Market Attractiveness Analysis, By Drug Type
13.2.4.Penicillin & Combinations
13.2.4.1. Amoxicillin
13.2.4.2. Amoxicillin+ Clavulanate Potassium
13.2.4.3. Others
13.2.5.Quinolones
13.2.5.1. Ciprofloxacin
13.2.5.2. Levofloxacin
13.2.5.3. Nalidixic acid
13.2.5.4. Norfloxacin
13.2.5.5. Others
13.2.6.Cephalosporin
13.2.6.1. Cefuroxime
13.2.6.2. Ceftriaxone
13.2.6.3. Cefixime
13.2.6.4. Cephalexin
13.2.7.Aminoglycoside Antibiotics
13.2.7.1. Amikacin
13.2.7.2. Gentamicin
13.2.8.Sulphonamides
13.2.8.1. Sulfamethoxazole + Trimethoprim
13.2.9.Azoles and Amphotericin B
13.2.10. Tetracycline
13.2.10.1.Doxycycline
13.2.11. Nitrofurans
13.2.11.1.Nitrofurantoin
13.2.12. Others
13.3. Market Value Forecast, By Distribution Channel
13.3.1.Y-o-Y Growth Projections, By Distribution Channel
13.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
13.3.3.Market Attractiveness Analysis, By Distribution Channel
13.3.4.Hospital Pharmacies
13.3.5.Gynecology and Urology Clinics
13.3.6.Drug Stores
13.3.7.Retail Pharmacies
13.3.8.Online Drug Stores
13.4. Market Value Forecast, By Indication
13.4.1.Y-o-Y Growth Projections, By Indication
13.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
13.4.3.Market Attractiveness Analysis, By Indication
13.4.4.Complicated UTI
13.4.5.Recurring Complicated UTI
13.4.6.Uncomplicated UTI
13.4.7.Neurogenic Bladder Infections
14. Japan Urinary Tract Infection Treatment Market Analysis
14.1. Market Value Forecast, By Drug Type
14.1.1.Y-o-Y Growth Projections, By Drug Type
14.1.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
14.1.3.Market Attractiveness Analysis, By Drug Type
14.1.4.Penicillin & Combinations
14.1.4.1. Amoxicillin
14.1.4.2. Amoxicillin+ Clavulanate Potassium
14.1.4.3. Others
14.1.5.Quinolones
14.1.5.1. Ciprofloxacin
14.1.5.2. Levofloxacin
14.1.5.3. Nalidixic acid
14.1.5.4. Norfloxacin
14.1.5.5. Others
14.1.6.Cephalosporin
14.1.6.1. Cefuroxime
14.1.6.2. Ceftriaxone
14.1.6.3. Cefixime
14.1.6.4. Cephalexin
14.1.7.Aminoglycoside Antibiotics
14.1.7.1. Amikacin
14.1.7.2. Gentamicin
14.1.8.Sulphonamides
14.1.8.1. Sulfamethoxazole + Trimethoprim
14.1.9.Azoles and Amphotericin B
14.1.10. Tetracycline
14.1.10.1.Doxycycline
14.1.11. Nitrofurans
14.1.11.1.Nitrofurantoin
14.1.12. Others
14.2. Market Value Forecast, By Distribution Channel
14.2.1.Y-o-Y Growth Projections, By Distribution Channel
14.2.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
14.2.3.Market Attractiveness Analysis, By Distribution Channel
14.2.4.Hospital Pharmacies
14.2.5.Gynecology and Urology Clinics
14.2.6.Drug Stores
14.2.7.Retail Pharmacies
14.2.8.Online Drug Stores
14.3. Market Value Forecast, By Indication
14.3.1.Y-o-Y Growth Projections, By Indication
14.3.2.Market Share & Basis Point (BPS) Analysis, By Indication
14.3.3.Market Attractiveness Analysis, By Indication
14.3.4.Complicated UTI
14.3.5.Recurring Complicated UTI
14.3.6.Uncomplicated UTI
14.3.7.Neurogenic Bladder Infections
15. MEA Urinary Tract Infection Treatment Market Analysis
15.1. Market Value Forecast, By Country
15.1.1.Y-o-Y Growth Projections, By Country
15.1.2.Market Share & Basis Point (BPS) Analysis, By Country
15.1.3.Market Attractiveness Analysis, By Country
15.1.4.GCC Countries
15.1.5.South Africa
15.1.6.North Africa
15.1.7.Rest of MEA
15.2. Market Value Forecast, By Drug Type
15.2.1.Y-o-Y Growth Projections, By Drug Type
15.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
15.2.3.Market Attractiveness Analysis, By Drug Type
15.2.4.Penicillin & Combinations
15.2.4.1. Amoxicillin
15.2.4.2. Amoxicillin+ Clavulanate Potassium
15.2.4.3. Others
15.2.5.Quinolones
15.2.5.1. Ciprofloxacin
15.2.5.2. Levofloxacin
15.2.5.3. Nalidixic acid
15.2.5.4. Norfloxacin
15.2.5.5. Others
15.2.6.Cephalosporin
15.2.6.1. Cefuroxime
15.2.6.2. Ceftriaxone
15.2.6.3. Cefixime
15.2.6.4. Cephalexin
15.2.7.Aminoglycoside Antibiotics
15.2.7.1. Amikacin
15.2.7.2. Gentamicin
15.2.8.Sulphonamides
15.2.8.1. Sulfamethoxazole + Trimethoprim
15.2.9.Azoles and Amphotericin B
15.2.10. Tetracycline
15.2.10.1.Doxycycline
15.2.11. Nitrofurans
15.2.11.1.Nitrofurantoin
15.2.12. Others
15.3. Market Value Forecast, By Distribution Channel
15.3.1.Y-o-Y Growth Projections, By Distribution Channel
15.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
15.3.3.Market Attractiveness Analysis, By Distribution Channel
15.3.4.Hospital Pharmacies
15.3.5.Gynecology and Urology Clinics
15.3.6.Drug Stores
15.3.7.Retail Pharmacies
15.3.8.Online Drug Stores
15.4. Market Value Forecast, By Indication
15.4.1.Y-o-Y Growth Projections, By Indication
15.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
15.4.3.Market Attractiveness Analysis, By Indication
15.4.4.Complicated UTI
15.4.5.Recurring Complicated UTI
15.4.6.Uncomplicated UTI
15.4.7.Neurogenic Bladder Infections
16. Competition Landscape
16.1. Competition Dashboard
16.2. Company Profiles Inclusions
16.2.1.Revenue
16.2.2.Products/Brand Offerings
16.2.3.Key developments
16.2.4.SWOT Analysis
16.3. Company Profile
16.3.1.Johnson & Johnson Private Ltd.
16.3.2.Boehringer Ingelheim GmbH
16.3.3.Cipla Ltd.
16.3.4.Bayer AG
16.3.5.GlaxoSmithKline Pharmaceuticals Ltd.
16.3.6.Pfizer Inc.
16.3.7.F. Hoffmann–La Roche Ltd.
16.3.8.Novartis AG
16.3.9.AstraZeneca plc
The Urinary Tract Infection Treatment Market has been segmented as below:
By Drug Type Analysis
• Sulphonamides
• Azoles and Amphotericin B
• Tetracycline
• Nitrofurans
• Aminoglycoside antibiotics
o Amikacin
o Gentamicin
• Cephalosporin
Ceftriaxone
Cefuroxime
Cefixime
Cephalexin
• Quinolones
Ciprofloxacin
Levofloxacin
Nalidixic acid
Norfloxacin
Others
• Penicillin & Combinations
Amoxicillin
Amoxicillin & Clavulanate Potassium
Others
By Indication Analysis
• Complicated UTI
• Recurring Complicated UTI
• Uncomplicated UTI
• Neurogenic Bladder Infections
By Distribution channel Analysis
• Hospital Pharmacies
• Gynaecology and Urology Clinics
• Drug Store
• Retail Pharmacies
• Online Drug Stores
By Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World
